CYP4F2-mediated ω-hydroxylation of 1-deoxysphingolipids reveals a new hepatic detoxification pathway

1-deoxysphingolipids (1-deoxySLs) are atypical, cytotoxic sphingolipids (SL) formed by the serine palmitoyltransferase through the alternative use of L-Alanine over its canonical substrate L-Serine. Elevated plasma levels of 1-deoxySLs have been implicated in metabolic and neurodegenerative diseases. Due to the missing C1 hydroxyl group, 1-deoxySLs cannot be converted into complex sphingolipids nor degraded via the canonical SL catabolic pathways. However, previous reports suggested a cytochrome P450 mediated {omega}-hydroxylation of 1-deoxySLs as a potential detoxification mechanism although the exacts downstream metabolism of these lipids remained unclear. We combined genome-wide association analysis with targeted lipid analysis to identify genes involved in 1-deoxySL metabolism. Functional validation was performed in cell culture models, enzyme assays, and through quantitative high-resolution mass spectrometry using isotope labelled synthetic standards.We identified a strong association between the CYP4F2 rs2108622 variant and plasma 1-deoxySL, implicating CYP4F2 is involved in 1-deoxySL metabolism. We demonstrated that CYP4F2 catalyzes the {omega}-hydroxylation of 1-deoxysphinganine, forming a previously uncharacterized hydroxylated sphingoid base. In liver cells, this metabolite was further metabolized via three distinct pathways: one forming the N-acyl, a second involving omega acylation and third resulting in omega carboxylation. All reactions generated a new spectrum of 1-deoxysphingolipids that are based on {omega}-hydroxylated 1-deoxySA as a precursor. The metabolic steps were confirmed by structural validation using synthetically prepared external standards. Importantly, {omega}-hydroxylation significantly attenuated the acute cytotoxicity of 1-deoxySLs in liver cells, indicating that this modification is the initiating step of a multi-branched metabolic clearance pathway. This study identifies CYP4F2 as a key enzyme initiating the hepatic clearance of atypical 1-deoxySLs, mitigating their cellular toxicity and revealing multiple downstream metabolic fates. Our findings highlight a previously unrecognized clearance mechanism for atypical sphingolipids with relevance to metabolic disease.